The Legal Examiner Mark The Legal Examiner Mark The Legal Examiner Mark search twitter facebook feed linkedin instagram google-plus avvo phone envelope checkmark mail-reply spinner error close
Skip to main content

The U.S. Food and drug Administration (FDA) is aware of a potential safety issue related to Avandia (rosigliazone), a drug used to treat type 2 diabetes.

Safety data from controlled clinical trials have demonstrated a potentially significant increase in the risk of heart attacks and heart-related deaths in patients taking Avandia. One study reported by The New York Times found that Avandia made by GlaxoSmithKline, doubled the risks of heart failure and raised the risks of heart attack by 42 percent. The Avandia controversy ignited in May 2007 when the New England Journal of Medicine published a combined analysis of more than 40 studies of Avandia that found that the drug significantly raised the risks of heart attack. In addition to the risks associated with heart failure, the drug has been linked to causing blindness and doubles the risks of bone fractures in women according to a study done by Wake forest University on four long-term studies. In June 2007 the FDA placed the strictest warning labels on Avandia because of all the risks associated with taking the drug.

Hilliard and Munoz LLP has the resources and legal skills to take on the largest Drug manufacturers in the world and have done so successfully in the past with other defective drugs that have been placed in consumers’ hands. Bob Hilliard is board certified by the state of Texas Board of Legal Specialization in Personal Injury Trial Law and Civil Trial Law. Hilliard and Munoz LLP has also handled class action law suits involving thousands of plaintiff’s nationwide. If you have questions relating to Avandia and have suffered heart failure from taking Avandia, we may be able to help you with any legal claims you are entitled to for your pain and suffering or loss of life by a loved one who had been taking Avandia.

For more information on this subject matter, please refer to the section on Drugs, Medical Devices, and Implants.

Comments are closed.

Of Interest